| Dataset | Phosphosite Textmining Biological Term Annotations |
| Category | structural or functional annotations |
| Type | biological term |
| Description | A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.|Tumors or cancer of the LIVER.|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. --2002|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. (Experimental Factor Ontology, EFO_0000182) |
| Similar Terms | |
| Downloads & Tools |
59 proteins co-occuring with the biological term hepatoma in abstracts of publications describing phosphosites from the Phosphosite Textmining Biological Term Annotations dataset.
| Symbol | Name |
|---|---|
| ACACA | acetyl-CoA carboxylase alpha |
| AHR | aryl hydrocarbon receptor |
| AKT1 | v-akt murine thymoma viral oncogene homolog 1 |
| BAD | BCL2-associated agonist of cell death |
| BAX | BCL2-associated X protein |
| BMX | BMX non-receptor tyrosine kinase |
| CDK5 | cyclin-dependent kinase 5 |
| CEACAM1 | carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
| CEBPA | CCAAT/enhancer binding protein (C/EBP), alpha |
| CEBPB | CCAAT/enhancer binding protein (C/EBP), beta |
| CFL1 | cofilin 1 (non-muscle) |
| CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa |
| DLC1 | DLC1 Rho GTPase activating protein |
| DLGAP5 | discs, large (Drosophila) homolog-associated protein 5 |
| EGFR | epidermal growth factor receptor |
| EIF2S1 | eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa |
| EIF4EBP1 | eukaryotic translation initiation factor 4E binding protein 1 |
| FAS | Fas cell surface death receptor |
| FASN | fatty acid synthase |
| FGF2 | fibroblast growth factor 2 (basic) |
| FOXO1 | forkhead box O1 |
| GSK3A | glycogen synthase kinase 3 alpha |
| GSK3B | glycogen synthase kinase 3 beta |
| HDGF | hepatoma-derived growth factor |
| HIST1H3A | histone cluster 1, H3a |
| HIST3H2BA | histone cluster 3, H2ba, pseudogene |
| IGFBP1 | insulin-like growth factor binding protein 1 |
| IL6ST | interleukin 6 signal transducer |
| INSR | insulin receptor |
| IRS1 | insulin receptor substrate 1 |
| IRS2 | insulin receptor substrate 2 |
| LIFR | leukemia inhibitory factor receptor alpha |
| MAPK1 | mitogen-activated protein kinase 1 |
| MAPK3 | mitogen-activated protein kinase 3 |
| MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 |
| MET | MET proto-oncogene, receptor tyrosine kinase |
| NFE2L2 | nuclear factor, erythroid 2-like 2 |
| NFKBIA | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
| NR1I2 | nuclear receptor subfamily 1, group I, member 2 |
| NR3C1 | nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
| PDE3B | phosphodiesterase 3B, cGMP-inhibited |
| PDHA1 | pyruvate dehydrogenase (lipoamide) alpha 1 |
| PLCG1 | phospholipase C, gamma 1 |
| PPARA | peroxisome proliferator-activated receptor alpha |
| PRKAA2 | protein kinase, AMP-activated, alpha 2 catalytic subunit |
| PRKCB | protein kinase C, beta |
| PRKCZ | protein kinase C, zeta |
| PTK2 | protein tyrosine kinase 2 |
| PTPN6 | protein tyrosine phosphatase, non-receptor type 6 |
| RELA | v-rel avian reticuloendotheliosis viral oncogene homolog A |
| RPS6KB1 | ribosomal protein S6 kinase, 70kDa, polypeptide 1 |
| SEC14L2 | SEC14-like 2 (S. cerevisiae) |
| SERPINA1 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 |
| SP1 | Sp1 transcription factor |
| SREBF1 | sterol regulatory element binding transcription factor 1 |
| STAT1 | signal transducer and activator of transcription 1, 91kDa |
| STAT3 | signal transducer and activator of transcription 3 (acute-phase response factor) |
| STAT5A | signal transducer and activator of transcription 5A |
| TP53 | tumor protein p53 |
